Myfortic

Embryo-fetal toxicity; rule out pregnancy with serum or urine pregnancy test immediately before starting therapy, and then another test 8–10 days later. Repeat pregnancy tests during routine follow-up visits. Increased risk of infections (eg, bacterial, viral, fungal, protozoal), lymphomas and other malignancies (eg, skin). New or reactivated viral infections (eg, polyomavirus associated nephropathy [PVAN], progressive multifocal leukoencephalopathy [PML], CMV, SARS-CoV-2); consider dose reduction if develops. Monitor for active HBV/HCV infection. Not interchangeable with other forms of mycophenolate. Avoid sun, UV light. Monitor CBCs weekly for first month, then twice monthly for the 2^nd and 3^rd months, then monthly during first year. If neutropenia or anemia occur, interrupt or reduce dose. Active serious digestive system disease, acute inflammatory syndrome, or renal impairment; monitor. Avoid in those with hypoxanthine-guanine phosphoribosyl transferase deficiency. Avoid blood donation during and for at least 6 weeks after discontinuation. Elderly. Pregnancy: avoid if safer treatment options are available. Counsel females of reproductive potential to use 2 forms of contraception (or 1 form if using IUDs, tubal sterilization, or if partner has had vasectomy) during therapy, and for 6 weeks after discontinuation unless patient chooses abstinence. Advise males (w. female partners) to use effective contraception and should not donate sperm during and for at least 90 days after discontinuation. Nursing mothers.